Ultime notizie per Nuvectis Pharma (NASDAQ:NVCT) Azioni

Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Nuvectis Pharma Inc

WIIM

AngloGold Ashanti shares are trading lower after HSBC downgraded the stock from Hold to Reduce and announced a price target of $35.

FANG

Diamondback Energy shares are trading higher after Truist Securities raised its price target on the stock from $238 to $242 and maintained a Buy rating.

Investment advisor Ross Gerber is calling out what he sees as unfair treatment in President Donald Trump&#8217;s tariff policy, accusing the administration of protecting corporate giants while leaving small businesses to suffer.
&#8220;So all the small businesses get to struggle and go [bankrupt] while Trump makes exceptions for most other Chinese imports from the [Magnificent] 7,&#8221; Gerber <a href="https://x.com/GerberKawasaki/status/1911086217044918298">posted</a> on X. &#8220;This is not only absurd, but just wrong. It's the art of the steal.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">So all the small businesses get to struggle and go BK while Trump makes exceptions for most other Chinese imports from the mag 7. This is not only absurd, but just wrong. It's the art of the steal.
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1911086217044918298?ref_src=twsrc%5Etfw">April 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Invest in the future of digital engagement: <a href="https://www.benzinga.com/money/vatom-adv">Own a piece of the $100 billion Metaverse for just $500</a>.</li>
</ul>
<h2 class="wp-block-heading">Big Tech Gets a Break</h2>
Gerber&#8217;s frustration followed news that the Trump administration had <a href="https://www.benzinga.com/25/04/44778464/trump-administration-grants-tariff-reprieve-to-tech-industry-apple-and-nvidia-among-beneficiaries">granted tariff exemptions</a> for smartphones, laptops and other electronics — a major win for tech firms like Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>). These products had been subject to steep import taxes as part of Trump's aggressive trade crackdown on China.
U.S. Customs and Border Protection listed the exemptions late Friday, applying retroactively from April 5. The list included semiconductors, memory chips and flat-panel displays—all critical components for companies in the so-called &#8220;Magnificent 7,&#8221; a group of high-performing tech stocks.
<h2 class="wp-block-heading">Small Businesses Say They're Getting Crushed</h2>
Critics say the carveouts expose a double standard. &#8220;Tariffs against big-tech Apple: ZERO. Tariffs against Mom-and-Pop Main Street businesses: 145%,&#8221; <a href="https://x.com/acedawg22/status/1911127552489369807">posted</a> a person in response to Gerber. Another user wrote: &#8220;Let them eat cake!&#8221;
Trending: With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.
In an April 4 <a href="https://www.youtube.com/watch?v=zLnX1SQfgJI">interview</a> with Tucker Carlson, Treasury Secretary Scott Bessent argued the stock drop wasn't Trump's fault. &#8220;If I were to analyze&#8230; what's happening with the market, I'd say it's more a Mag 7 problem, not a MAGA one,&#8221; Bessent said, blaming the downturn on China's new AI tool, <a href="https://www.benzinga.com/topic/deepseek">DeepSeek</a>, rather than the president's economic policies.
But many economists and even Federal Reserve officials disagree, pointing to the market chaos and inflation fears triggered by Trump's escalating tariff war. Consumer confidence has plunged, and the S&amp;P 500 has seen its wildest swings since the 2020 pandemic.
<h2 class="wp-block-heading">Relief Might Not Last</h2>
Any relief for tech companies could be short-lived. On Sunday, Trump posted that the excluded products were still subject to the existing 20% fentanyl-related tariffs and would be reassigned under a new national security investigation.
&#8220;There was no tariff &#8216;exception&#8217;,&#8221; Trump wrote on <a href="https://truthsocial.com/@realDonaldTrump/posts/114332337028519855">Truth Social</a>. &#8220;These products are just moving to a different tariff &#8216;bucket.'&#8221;
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Commerce Secretary Howard Lutnick confirmed the administration plans to impose new duties within two months targeting semiconductors, smartphones and computers. &#8220;These are things that are national security, that we need to be made in America,&#8221; Lutnick told <a href="https://www.youtube.com/watch?v=cYGb2Sgy_Vk">ABC News</a>.
Critics like Sen. Elizabeth Warren (D-MA) blasted the administration's inconsistent moves. &#8220;There is no tariff policy — only chaos and corruption,&#8221; she <a href="https://www.youtube.com/watch?v=eTNcjSsxBVY">said</a> Sunday on ABC's &#8220;This Week.&#8221;
<h2 class="wp-block-heading">Market Mayhem</h2>
The on-again, off-again nature of Trump's tariff strategy has sent <a href="https://www.benzinga.com/25/04/44774499/wall-street-panic-extends-to-main-street-as-us-china-trade-war-escalates-bond-vigilantes-make-a-comeback-this-week-in-markets">shock waves</a> through the economy. Investors have dumped bonds, the <a href="https://www.benzinga.com/markets/equities/25/04/44768702/foreigners-dump-the-dollar-gold-and-yen-act-as-safe-haven-jpmorgan-helps-stock-market-cooler-ppi">dollar has slumped</a> and gold has hit record highs. China, meanwhile, slapped a <a href="https://www.benzinga.com/markets/25/04/44756353/xi-jinping-says-there-are-no-winners-in-tariff-war-as-china-slaps-125-tariffs-on-us-goods-urges-trump-to-immediately-correct-wrongdoings">125% retaliatory tariff on U.S. goods</a> and warned that any future hikes would be ignored.
Despite the turbulence, Bessent insisted the administration maintains a &#8220;strong-dollar policy&#8221; and dismissed suggestions that tariffs are a backdoor attempt to devalue the currency.
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

News

AAPL

DELL

NVDA

'Art Of The Steal'—Ross Gerber Says Small Businesses Get To 'Go Bankrupt' While Trump Makes Exceptions For MAG 7 Chinese Imports

The <a href="https://www.benzinga.com/topic/cybersecurity">cybersecurity sector</a> may be breathing a sigh of relief after a deal was reached to continue funding for the Common Vulnerabilities and Exposures database, commonly known as the CVE program.
What Happened: The 25-year-old CVE program is used to identify cybersecurity vulnerabilities and has been considered a vital part of <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44501515/cybersecurity-stocks-to-outperform-its-the-one-line-item-that-no-company-in-the-world-is-cutting-josh-brown">the cybersecurity sector.</a>
News spread this week that funding for the CVE program expired on April 16 and a contract with the U.S. Department of Homeland Security had not been renewed. However, in a last-minute turnaround, the program was reinstated, according to a Forbes <a href="https://www.forbes.com/sites/kateoflahertyuk/2025/04/16/cve-program-funding-cut-what-it-means-and-what-to-do-next/">report</a>.
"The CVE Program is invaluable to cyber community and a priority of CISA. Last night, CISA executed the option period on the contract to ensure there will be no lapse in critical CVE services," a CISA (Cybersecurity and Infrastructure Security Agency) spokesperson told Forbes.
The report said the CISA's extension of funding will last 11 months.
A new body, which includes a subset of the CVE Board, will break off and maintain the CVE Program, according to the report. 
"The CVE Foundation has been formally established to ensure the long-term viability, stability, and independence of the Common Vulnerabilities and Exposures Program, a critical pillar of the global cybersecurity infrastructure for 25 years," the new CVE governing body said.
Read Also: <a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44241995/cybersecurity-report-flags-7-major-threats-against-governments-corporations-stocks-and-etfs-to-watch">Cybersecurity Report Flags 7 Major Threats Against Governments, Corporations: Stocks And ETFs To Watch</a>
Why It's Important: Experts warned that the end of the CVE Program could lead to increased vulnerabilities in the cybersecurity sector.
"Without CVE, defenders are at a massive disadvantage against global cyber threats," CVE Board Member Kent Landfield said. "CVE, as a cornerstone of the global cybersecurity ecosystem, is too important to be vulnerable itself."
If the CVE had not been able to continue its funding, the list of logged vulnerabilities would have ended, and organizations could have been more vulnerable to attacks.
The funding extension eases worries temporarily but leaves questions about the future of the CVE, which comes as cybersecurity attacks have increased and remain a key concern for large companies.
Investors seeking exposure to the cybersecurity sector have several options, including individual stocks and ETFs. These are the largest ETFs covering the sector:
<ul>
<li>First Trust Nasdaq Cybersecurity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIBR#NASDAQ">CIBR</a>)</li>
<li>Amplify Cybersecurity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HACK#NYSE">HACK</a>)</li>
<li>Global X Cybersecurity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUG#NASDAQ">BUG</a>)</li>
<li>iShares Cybersecurity And Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHAK#NYSE">IHAK</a>)</li>
</ul>
In the ETFs, some of the top holdings include CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) and Okta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>).
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44859945/whistleblower-alleges-doge-involved-in-major-cybersecurity-breach-at-us-labor-agency">Whistleblower Says DOGE May Have Caused Major Cybersecurity Breach At US Labor Agency</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Trading Ideas

ETFs

AVGO

CHKP

CIBR

CRWD

CSCO

HACK

IHAK

OKTA

Pillar Of America's Cyber Security Lost Funding Temporarily: What Investors Should Know About CVE Program, Funding Extension

Equitable Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) has outperformed the market over the past 5 years by 12.04% on an annualized basis producing an average annual return of 26.03%. Currently, Equitable Holdings has a market capitalization of $13.54 billion. 
Buying $100 In EQH: If an investor had bought $100 of EQH stock 5 years ago, it would be worth $303.39 today based on a price of $44.00 for EQH at the time of writing.
<h3>Equitable Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744902915_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Fidelity National Information Services shares are trading higher after the company announced it will buy a global payments issuer solutions business for $13.5 billion and provided Q1 guidance.

Loop Capital analyst Jeffrey Stevenson maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Hold and lowers the price target from $55 to $49.

Price Target

Analyst Ratings

AZEK

Loop Capital Maintains Hold on AZEK Co, Lowers Price Target to $49

Lockheed Martin shares are trading lower. The company announced management changes for its CFO and senior VP roles.

Barclays analyst Jason Goldberg maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Overweight and lowers the price target from $61 to $56.

Barclays Maintains Overweight on U.S. Bancorp, Lowers Price Target to $56

If you hold U.S.-listed Chinese stocks like Alibaba Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NASDAQ">BABA</a>), JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) or PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), you may soon face serious liquidity risks, as delisting threats tied to geopolitical and regulatory frictions between Washington and Beijing <a href="https://www.benzinga.com/topic/tariffs">mount with fresh urgency.</a>
In a note shared Thursday, Goldman Sachs analyst Kinger Lau, CFA, said delisting fears for Chinese American Depositary Receipts (ADRs) are rising again, driven by escalating trade tensions and new policy guidance from U.S. officials, including President Donald Trump&#8216;s America First Investment Policy and Treasury Secretary Scott Bessent's statement that "everything is on the table" in the response to China's retaliatory tariffs.
According to Goldman Sachs&#8217; ADR Delisting Barometer, there is currently a 66% probability of delisting risk embedded in Chinese ADRs. A full pricing in of delisting risk could lead to a 9% drop in ADR valuations from current levels. 
&#8220;U.S. listings by Chinese companies is widely regarded as an embodiment of financial market relations and a leverage for the potential negotiation between the two nations,&#8221; Lau wrote.
<h1 class="wp-block-heading">How High Are The Stakes?</h1>
&#8220;We estimate that U.S. institutional investors currently own around U.S.$830 billion of Chinese stocks across A shares, H shares and ADRs,&#8221; Goldman Sachs stated. Of this, approximately $250 billion is tied up in ADRs specifically.
At the same time, Chinese investors could be forced to offload up to $1.7 trillion in U.S. financial assets, including approximately $370 billion in equities and $1.3 trillion in bonds.
This extreme scenario — which alludes to a full investment ban — would represent the largest forced unwind of cross-border holdings in modern financial history.
<h1 class="wp-block-heading">Who Gets Hit The Hardest?</h1>
According to Goldman's analysis, 5% of Alibaba's and 3% of PDD's market cap is owned by U.S. institutions that currently don't own other Hong Kong-listed stocks such as Tencent or Meituan. That means they may not have operational flexibility to pivot to Hong Kong in the event of delisting.
Roughly 20% of U.S. institutional holdings in top ADRs — equivalent to 7% of the total market cap — may face similar constraints, meaning they may be forced sellers.
For Alibaba, there are 1,275 institutional holders globally, and institutional investors collectively own 50% of the company&#8217;s outstanding shares. Out of that, 26% of Alibaba's total shares are held by U.S.-based institutions, with 176 U.S. institutional investors holding positions larger than 0.005% of the company's total shares.
For PDD, the figures are more concentrated: it has 1,006 institutional holders, with institutions holding 31% of the stock overall. 16% of the total shares are held by U.S. institutional investors, and there are 107 U.S.-based institutional holders with significant stakes (above 0.005% ownership).
In short, the data suggests Alibaba has both broader and deeper institutional engagement, especially from U.S. investors, compared to PDD. This means that, in the event of a U.S. delisting, Alibaba could see a greater volume of forced selling from U.S. institutional investors due to the larger size and scale of U.S. holdings.
<h1 class="wp-block-heading">Are ETFs And Derivatives at Risk?</h1>
Yes. Passive funds and ETF products are particularly exposed. The KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>) has 33% of its assets in ADRs, half of which do not have Hong Kong listings, making it vulnerable in a forced delisting scenario.
Other funds, like the iShares MSCI China ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NYSE">MCHI</a>), have already shifted weightings from ADRs to Hong Kong shares, thanks to changes in primary ticker designations by index providers like MSCI.
In derivatives markets, any forced delisting of ADRs could trigger early termination events under ISDA contracts, potentially unwinding outstanding options and swaps linked to these securities.
<h1 class="wp-block-heading">What Happens In A Delisting Event?</h1>
If a delisting takes place, investors may have a few paths forward depending on how the company is structured. For firms with dual listings, investors can convert their ADRs into Hong Kong-listed shares through the depositary bank. 
This process typically takes about two business days and may involve fees and applicable taxes. In some cases, investors might be able to sell their shares on over-the-counter (OTC) markets, although this route is blocked for companies delisted under the Holding Foreign Companies Accountable Act (HFCAA) or sanctioned by the Office of Foreign Assets Control (OFAC). 
If no action is taken by the investor, the ADR program will eventually be terminated and the depositary will sell the underlying shares, distributing the net proceeds in cash after deducting fees.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44862662/trump-pressures-fed-as-ecb-delivers-7th-straight-rate-cut">Trump Pressures Fed As ECB Delivers 7th Straight Rate Cut</a></li>
</ul>
Photo: Shutterstock

Asia

Equities

Government

Large Cap

Macro Economic Events

Regulations

Specialty ETFs

Global

Econ #s

Economics

Tech

BABA

KWEB

MCHI

Citigourp Global Markets 2% Protected Notes Linked To The Djia

US-Listed Chinese Stocks Face $250 Billion Forced Selling Risk As Delisting Fears Emerge: What Investors Need To Know

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected first-quarter <a href="https://www.benzinga.com/quote/abt/earnings">adjusted EPS results</a> on Wednesday.
Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said Robert Ford, chairman and CEO of Abbott. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."
Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.
Abbott Laboratories shares gained 0.9% to trade at $130.81 on Thursday.
These analysts made changes to their price targets on Abbott Laboratories following earnings announcement.
<ul>
<li>Jefferies analyst Matthew Taylor maintained Abbott Laboratories with a Hold and raised the price target from $135 to $137.</li>
<li>Stifel analyst Rick Wise maintained the stock with a Buy and raised the price target from $135 to $145.</li>
<li>Barclays analyst Matt Miksic maintained Abbott Laboratories with an Overweight and raised the price target from $158 to $159.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png" alt="" class="wp-image-877000" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44866413/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-3">Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Earnings

Markets

These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings

Barclays analyst Julien Roch maintains Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) with a Overweight and lowers the price target from $110 to $105.

Barclays Maintains Overweight on Omnicom Group, Lowers Price Target to $105

Westamerica Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WABC#NASDAQ">WABC</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.11 by 4.5 percent. This is a 15.33 percent decrease over earnings of $1.37 per share from the same period last year.

Earnings Beats

WABC

Westamerica Bancorp Q1 EPS $1.16 Beats $1.11 Estimate

Barclays analyst Matt Miksic maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Equal-Weight and lowers the price target from $166 to $165.

Barclays Maintains Equal-Weight on Johnson & Johnson, Lowers Price Target to $165

Barclays analyst Manav Patnaik maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Overweight and lowers the price target from $300 to $275.

Barclays Maintains Overweight on Ecolab, Lowers Price Target to $275

Barclays analyst Brandon Oglenski maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Overweight and lowers the price target from $35 to $31.

Barclays Maintains Overweight on CSX, Lowers Price Target to $31

Barclays analyst Jason Goldberg maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Equal-Weight and lowers the price target from $52 to $49.

Barclays Maintains Equal-Weight on Citizens Financial Group, Lowers Price Target to $49

The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) posted weaker-than-expected first-quarter <a href="https://www.benzinga.com/quote/PGR/earnings">results on Wednesday</a>.
Progressive posted adjusted earnings of $4.66 per share, missing market estimates of $4.81 per share. The company's quarterly sales came in at $19.409 billion missing expectations of $21.626 billion.
Progressive shares fell 2.1% to trade at $269.42 on Thursday.
These analysts made changes to their price targets on Progressive following earnings announcement.
<ul>
<li>B of A Securities analyst Joshua Shanker maintained Progressive with a Neutral rating and raised the price target from $289 to $297.</li>
<li>BMO Capital analyst Michael Zaremski maintained the stock with an Outperform rating and increased the price target from $282 to $288.</li>
<li>Keefe, Bruyette &amp; Woods analyst Meyer Shields downgraded Progressive from Outperform to Market Perform and maintained the price target of $288.</li>
</ul>
Considering buying PGR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17110424/image-23-1024x600.png" alt="" class="wp-image-876969" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17110424/image-23-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17110424/image-23-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17110424/image-23-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17110424/image-23.png 1075w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44866413/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-3">Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a> </li>
</ul>
Photo via Shutterstock

These Analysts Revise Their Forecasts On Progressive After Q1 Earnings

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $158 to $159.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $159

Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is in the spotlight ahead of earnings Thursday. Here&#8217;s what you <a href="https://www.benzinga.com//node/44857276">need to know.</a>
The Details: Netflix will report earnings for the first-quarter after the market closes today. Analysts&#8217; estimate earnings per share of $5.72 and revenue of $10.52 billion, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
The company <a href="https://www.benzinga.com/news/earnings/25/01/43114866/netflix-q4-earnings-record-subscribers-nfl-squid-game-push-past-highest-expectations">previously guided revenue</a> to be about $10.42 billion, which would represent an 11.2% year-over-year increase. It also guided earnings per share of $5.58 and operating income of approximately $2.94 billion for the first quarter.
In its letter to shareholders at the end of 2024, the company said, &#8220;We enter 2025 with strong momentum, coming off a year with record net additions (41M) and having re-accelerated growth (16% increase in revenue). Moreover, we're in a leadership position in terms of engagement (approximately two hours per paid membership per day), revenue ($39B) and profit ($10B in operating income) in a market that is continuing to expand.&#8221;
Ahead of earnings, Needham analyst Laura Martin reiterated a Buy rating on Netflix and maintained a&nbsp;$1126&nbsp;price target.
See Also: <a href="https://www.benzinga.com/news/25/04/44865115/figure-ai-shakes-silicon-valley-with-39-5b-valuation-200000-robots-promised-by-2029-beating-out-spacex-and-openai">Figure AI Shakes Silicon Valley With $39.5B Valuation, 200,000 Robots Promised By 2029, Beating Out SpaceX And OpenAI</a>
NFLX Price Action: At the time of writing, Netflix stock is trading 0.51% higher at $966.72, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: Courtesy of Netflix, Inc.

Movers

NFLX

What's Going On Netflix Shares Thursday?

Press Releases

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Financing

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

Comments

Nuvectis Pharma

Notizie

Ultime notizie per Nuvectis Pharma (NASDAQ:NVCT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO